Drug Development

Phase I/II trial of typhoid fever vaccine initiated

Published in Vaccine Weekly, March 8th, 2006

Avant Immunotherapeutics, Inc., (AVAN) announced the start of a placebo-controlled, double-blind phase I/II study of its typhoid fever vaccine candidate, Ty800.

The clinical trial, sponsored by the National Institute of Allergy and Infectious Disease (NIAID), a component of the National Institutes of Health (NIH), is being conducted at the Cincinnati Children's Hospital Medical Center.

The phase I/II study is an inpatient dose-escalating clinical trial aimed at determining the safety and immunogenicity of the single-dose, oral Ty800 vaccine. The trial will evaluate three escalating dose levels of the vaccine, in approximately 54 healthy adult...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2006-03-08)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry